Cationic nanoparticles for delivery of CpG oligodeoxynucleotide and ovalbumin: In vitro and in vivo assessment

Journal of Biomedical Nanotechnology

Volumn 3, Issue 1, 2007, Pages 97-106

  Patel, Jigna D ^a   Gandhapudi, Siva ^b   Jones, Julia ^b   O'Carra, Ronan ^a   Woodward, Jerold G ^b   Mumper, Russell J ^a  

^a University of Kentucky   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Adjuvants; Antigen presentation; CpG; Nanoparticles; OT 1 cells; Ovalbumin; Th1 responses

Indexed keywords

CD8 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NANOPARTICLE; OVALBUMIN; T LYMPHOCYTE RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; CD8+ T LYMPHOCYTE; CONFERENCE PAPER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MOUSE; NONHUMAN; T LYMPHOCYTE;

EID: 45849133797     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2007.007     Document Type: Conference Paper

References (42)

1. R. K. Gupta, E. H. Relyveld, E. B. Lindblad, B. Bizzini, S. Ben-Efraim, and C. K. Gupta, Adjuvants - A balance between toxicity and adjuvanticity. Vaccine 11, 293 (1993).
2. J. C. Cox and A. R. Coulter, Adjuvants - A classification and review of their modes of action. Vaccine 15, 248 (1997).
3. J. Kazzaz, M. Singh, M. Ugozzoli, J. Chesko, E. Soenawan, and T. D. O'Hagan, Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J. Control. Release 110, 566 (2006).
4. M. Singh and I. Srivastava, Advances in vaccine adjuvants for infectious diseases. Curr. HIV Res. 1, 309 (2003),
5. S. Thoelen, P. Van Damme, C. Mathei, G. Leroux-Roels, I. Desombere, A. Safary, P. Vandepapeliere, M. Slaoui, and A. Meheus, Safety and inummogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 16, 708 (1998).
6. A. Moore, L. McCarthy, and K. H. Mills, The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Tb2 to Th1. Vaccine 17, 2517 (1999).
7. M. Diwan, P. Elamanchili, M. Cao, and J. Samuel, Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery. Curr Drug Deliv. 1, 405 (2004).
8. M. Rao, G. R. Matyas, T. C. Vancott, D. L. Birx, and C. R. Alving, Immunostimulatory CpG motifs induce CTL responses to HIV type I oligomeric gp140 envelope protein. Immunol. Cell. Biol. 82, 523 (2004).
9. A. M. Krieg, A. K. Yi, S. Matson, T. J. Waldschmidt, G. A. Bishop, R. Teasdale, G. A. Koretzky, and D. M. Klinman, CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546 (1995).
10. D. M. Klinman, A. K. Yi, S. L. Beaucage, J. Conover, and A. M. Krieg, CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. USA 93, 2879 (1996).
11. T. Sparwasser, R. M. Vabulas, B. Villmow, G. B. Lipford, and H. Wagner, Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur. J. Immunol. 30, 3591 (2000).
12. T. Sparwasser, E. S. Koch, R. M. Vabulas, K. Heeg, G. B. Lipford, J. W. Ellwart and H. Wagner, Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Inununol. 28, 2045 (1998).
13. D. M. Klinman, D. Currie, I. Gursel, and D. Verthelyi, Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev. 199, 201 (2004).
14. M. J. McCluskie, R. D. Weeratna, and H. L. Davis, The role of CpG in DNA vaccines. Springer Semin. Immunopathol. 22, 125 (2000).
15. Y. Van der Stede, F. Verdonck, S. Vancaeneghem, E. Cox, and B. M. Goddeeris, CpG-oligodinuclootides as an effective adjuvant in pigs for intramuscular immunizations. Vet. Immunol. Immunopathol. 86, 31 (2002).
16. M. J. McCluskie, R. D. Weeratna, and H. L. Davis, The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. Vaccine 19, 2657 (2001).
17. B. Maletto, A. Ropolo, V. Moron, and M. C. Pistoresi-Palencia, CpG-DNA stimulates cellular and humoral immunity and promotes Th 1 differentiation in aged BALB/c mice. J. Leukoc. Biol.72, 447 ( 2002).
18. R. D. Weeratna, C. L. Brazolot Milian, M. J. McCluskie, and H. L. Davis, CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol. Med. Microbiol. 32, 65 ( 2001).
19. C. L. Brazolot Milian, R. Weeratna, A. M. Krieg, C. A. Siegrist, and H. L. Davis, CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc. Natl. Acad. Sci. USA 95, 15553 (1998).
20. M. Singh, G. Ott, J. Kazzaz, M. Ugozzoli, M. Briones, J. Donnelly, and D. T. O'Hagan, Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA. Pharm. Res. 18, 1476 (2001).
21. I. Gursel, M. Gursel, K. J. Ishii, and D. M. Klinman, Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J. Immunol. 167, 3324 (2001).
22. D. T. O'Hagan, M. Singh, J. Kazzaz, M. Ugozzoli, M. Briones, J. Donnelly, and G. Ott, Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. Vaccine 20, 3389 (2002).
23. Z. Cui and R. J. Mumper, Topical immunization using nanoengi-neered genetic vaccines. J. Control. Release 91, 173 (2002).
24. Z. Cui and R. J. Mumper, Genetic immunization using nanoparticles engineered from microemulsion precursors. Pharm. Res. 19, 939 ( 2002).
25. Z. Cui and R. J. Mumper, Coating of cationized protein on engineered nanoparticles results in enhanced immune responses. Int. J. Pharm. 238, 229 (2002).
26. Z. Cui, J. Patel, M. Tuzova, P. Ray, R. Phillips, J. G. Woodward, A. Nath, and R. J. Mumper, Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles. Vaccine 22, 2631 (2004).
27. J. M. Koziara, J. J. Oh, W. S. Akers, S. P. Ferraris, and R. J. Mumper, Blood compatibility of cetyl alcohoUpolysorbate-based nanoparticles. Pharm. Res. 22, 1821 (2005).
28. J. M. Koziara, P. R. Lockman, D. D. Allen, and R. J. Mumper, In situ blood-brain barrier transport of nanoparticles. Pharm. Res. 20, 1772 (2003).
29. S K. Kim, D. S. Reed, S. Olson, M. J. Schnell, J. K. Rose, P. A. Morton, and L. Lefrancois, Generation of mucosal cytotoxic T cells against soluble protein by tissue-specific environmental and costimulatory signals. Proc. Natl. Acad. Sci. USA 95, 10814 (1998).
30. H. Sun, K. G. Pollock, and J. M. Brewer, Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro. Vaccine 21, 849 (2003).
31. M. E. Lutsiak, D. R. Robinson, C. Coester, G. S. Kwon, and J. Samuel, Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro. Pharm. Res. 19, 1480 ( 2002).
32. P. Elamanchili, M. Diwan, M. Cao, and J. Samuel, Characterization of poly(D,L-lactic-co-glycolic acid) based nanoparticulate system for enhanced delivery of antigens to dendritic cells. Vaccine 22, 2406 (2004).
33. T. L. Warren, S. K. Bhatia, A. M. Acosta, C. E. Dahle, T. L. Ratliff, A. M. Krieg, and G. J. Weiner, APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. J. Immunol. 165, 6244 (2000).
34. Y. J. Kwon, S. M. Standley, S. L. Goh, and J. M. Frechet, Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles. J. Control. Release 105, 199 (2005).
35. P. Guermonprez, J. Valladeau, L. Zitvogel, C. Thery, and S. Amigorena, Antigen presentation and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 20, 621 (2002).
36. X. Jiao, R. Y. Wang, Q. Qiu, H. J. Alter, and J. W. Shih, Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by codelivery of protein antigen and CpG with cationic liposomes. J. Gen. Virol. 85, 1545 (2004).
37. C. M. Snapper and W. E. Paul, Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236, 944 (1987).
38. R. D. Weeratna, S. R. Makinen, M. J. McCluskie, and H. L. Davis, TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 23, 5263 (2005).
39. M. Diwan, M. Tafaghodi, and J. Samuel, Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J. Control. Release 85, 247 (2002).
40. T. Liu, T. Matsuguchi, N. Tsuboi, T. Yajima, and Y. Yoshikai, Differences in expression of toll-like receptors and their reactivities in dendritic cells in BALB/c and C57BL/6 mice. Infect. Immun. 70, 6638 (2002).
41. D. M. Klinman, Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4, 249 (2004).
42. S. A. Halperin, G. Van Nest, B. Smith, S. Abtahi, H. Whiley, and J. J. Eiden, A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 21, 2461 ( 2003).